



## **Mersana Therapeutics to Present at Upcoming Investor Conferences**

May 24, 2023

CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences:

### **TD Cowen 4<sup>th</sup> Annual Oncology Innovation Summit**

Format: Fireside Chat

Date/Time: Wednesday, May 31, 2023, at 10:00 a.m. Eastern Time

### **Jefferies Healthcare Conference**

Format: Presentation

Date/Time: Wednesday, June 7, 2023, at 9:00 a.m. Eastern Time

Live webcasts of these events will be available on the Investors & Media section of Mersana's website at [www.mersana.com](http://www.mersana.com). Archived replays will be available for approximately 90 days following the events.

### **About Mersana Therapeutics**

Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana's lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer; UPGRADE-A, a Phase 1 clinical trial evaluating UpRi in combination with carboplatin; and UP-NEXT, a Phase 3 clinical trial of UpRi as monotherapy maintenance following treatment with platinum doublets in recurrent platinum-sensitive ovarian cancer. Mersana's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase 1 clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets. In addition, multiple partners are using Mersana's platforms to advance their ADC pipelines. Mersana routinely posts information that may be useful to investors on the "Investors & Media" section of its website at [www.mersana.com](http://www.mersana.com).

### **Contact:**

Jason Fredette  
617-498-0020

[jason.fredette@mersana.com](mailto:jason.fredette@mersana.com)